The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 105 results:
Author [ Title(Desc)] Type Year
Filters: Author is Katsiki, Niki  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
Katsiki, N., Doumas M., Athyros V. G., & Karagiannis A. (2015).  Hyperuricemia as a risk factor for cardiovascular disease.. Expert Rev Cardiovasc Ther. 13(1), 19-20.
I
Athyros, V. G., Tziomalos K., Katsiki N., Gossios T. D., Giouleme O., Anagnostis P., et al. (2013).  The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study.. Curr Vasc Pharmacol. 11(5), 779-84.
Athyros, V. G., Hatzitolios A. I., Karagiannis A., Savopoulos C., Katsiki N., Tziomalos K., et al. (2011).  IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.. Arch Med Sci. 7(6), 984-92.
Katsiki, N., & Hatzitolios A. I. (2010).  Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.. Curr Opin Obstet Gynecol. 22(6), 466-76.
L
Katsiki, N., Doumas M., & Mikhailidis D. P. (2016).  Lipids, Statins and Heart Failure: An Update.. Curr Pharm Des. 22(31), 4796-4806.
M
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.. Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
Anagnostis, P., Paschou S. A., Katsiki N., Krikidis D., Lambrinoudaki I., & Goulis D. G. (2019).  Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?. Curr Vasc Pharmacol. 17(6), 564-572.
Koumaras, C., Katsiki N., Athyros V. G., & Karagiannis A. (2013).  Metabolic syndrome and arterial stiffness: the past, the present and the future.. J Cardiovasc Med (Hagerstown). 14(10), 687-9.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Metabolic syndrome and non-cardiac vascular diseases: an update from human studies.. Curr Pharm Des. 20(31), 4944-52.
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Metabolic syndrome in clinical practice.. Cardiol J. 21(2), 209.
N
Katsiki, N., Hatzitolios A. I., & Mikhailidis D. P. (2011).  Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?. Ann Med. 43(4), 249-58.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations.. Angiology. 64(8), 572-5.
Athyros, V. G., Polyzos S. A., Kountouras J., Katsiki N., Anagnostis P., Doumas M., et al. (2019).  Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.. Curr Vasc Pharmacol.
Athyros, V. G., Tziomalos K., Katsiki N., & Mikhailidis D. P. (2014).  Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.. Curr Pharm Des. 20(40), 6215-9.
O
Katsiki, N., Anagnostis P., Kotsa K., Goulis D. G., & Mikhailidis D. P. (2019).  Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus.. Curr Pharm Des. 25(18), 2051-2059.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
P
Katsiki, N., Hatzitolios A. I., & Mikhailidis D. P. (2011).  Passive smoking: the democratic right of nonsmokers to survive.. Angiology. 62(7), 520-2.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Peripheral artery disease in patients with type 2 diabetes.. J Diabetes Complications. 28(6), 912.
Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., et al. (2018).  Pharmacotherapy of type 2 diabetes: An update.. Metabolism. 78, 13-42.
Papanas, N., Katsiki N., Hatzitolios A. I., & Maltezos E. (2011).  Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus.. Expert Opin Pharmacother. 12(10), 1457-61.
Baltazi, M., Katsiki N., Savopoulos C., Iliadis F., Koliakos G., & Hatzitolios A. I. (2011).  Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study.. Am J Cardiovasc Dis. 1(1), 48-59.
Katsiki, N., Doumas M., Athyros V. G., & Karagiannis A. (2014).  Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit.. Expert Rev Cardiovasc Ther. 12(3), 295-6.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.. Circ J. 77(5), 1348.
Athyros, V. G., Katsiki N., Tziomalos K., & Karagiannis A. (2011).  Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 5, 226-30.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.